Cases of cervical cancer will be reduced by up to 70 per cent with
the introduction of a new vaccine into the national immunisation
programme.
The Department of Health has agreed, in principle, to accept JCVI
advice that HPV vaccines should be introduced routinely for girls
aged around 12-13 years, subject to independent peer review of the
cost benefit analysis.
Funding for this will be considered in the context of the
Comprehensive Spending Review.
Human Papilloma Viruses cause 99 per cent of invasive cervical
cancer. The vaccine protects against the viruses responsible for
about 70% of cases.
Routine vaccination of girls could start as early as autumn 2008.
Details of the programme will be finalised over the next few months,
following further advice from JCVI and discussions with the NHS on
the implementation of the programme.
Public Health Minister Caroline Flint said:
“Cervical cancer is the second most common cancer of women worldwide.
In the UK alone, the lifetime risk of developing cervical cancer is
one in 116.
“It is great news that vaccines have been developed that protect
women against this form of cancer and I am delighted to announce that
we intend, in principle, to introduce an HPV vaccine into the
national immunisation programme.
“The benefits of introducing this vaccine will be felt by women and
their families for generations to come. In England, 2221 new cases of
invasive cervical cancer were diagnosed in 2004 alone. In addition
around 200,000 women in England are identified through the cervical
screening programme (smear tests) as having a pre-cancerous change.
“This vaccine will prevent many women from catching the HPV virus in
the first place, potentially saving hundreds of lives.
“A significant amount of planning is required before we can introduce
the immunisation into our programme. We are still working on the
details and logistics, and will work closely with the NHS to ensure
the vaccination can be delivered effectively. However, we are hoping
that girls will start being vaccinated from as early as 2008.”
The highly successful and comprehensive cervical screening programme
(smear tests) will continue after an HPV vaccine has been introduced.
This is because of the gap between the age of vaccination and age of
first screening. Also, screening will be required as the vaccine
does not protect against all HPV types that may cause cervical
cancer.
1. The Joint Committee for Vaccination and Immunisation (JCVI) has
advised that HPV vaccines are clearly beneficial. It has commissioned
a cost-effectiveness analysis which will be the subject of an
external peer review. The JCVI is expected to make their formal
recommendation to the Government at their next meeting on 17 October
2007.
2. The JCVI provides the Department of Health with independent
expert advice on all vaccine issues.
3. Human papilloma virus is a sexually transmitted virus that causes
99 per cent of invasive cervical cancer.
4. To ensure maximum benefit and protection from this vaccine, it
would be necessary to administer it before the onset of sexual
activity.
Department of Health, UK Continue reading